Table 3.
Risk factors associated with mortality in kidney transplant recipients with COVID-19 diagnosis during the initial 6 months after transplantation
| Variable | Univariate analysis, hazard ratio (95% CI) | P-value | Multivariate analysis, hazard ratio (95% CI) | P-value |
|---|---|---|---|---|
| Patient age >65 years | 0.985 (0.939–1.034) | .007 | ||
| Thymoglobulin induction | 1.955 (0.880–4.342) | .100 | ||
| Patient age (years) and induction | ||||
| >65 and thymoglobulin | 1 (reference) | 1 (reference) | ||
| >65 and basiliximab | 0.397 (0.174–0.905) | .028 | 0.425 (0.187–0.967) | .041 |
| <65 and thymoglobulin | 0.049 (0.011–0.225) | .000 | 0.095 (0.026–0.349) | .000 |
| <65 and basiliximab | 0.111 (0.035–0.357) | .000 | 0.104 (0.032–0.340) | .000 |
| Diabetes | 2.809 (0.908–4.579) | .038 | 1.821 (0.541–2.584) | .674 |
| BMI >30 kg/m2 | 3.021 (1.511–6.024) | .002 | 2.439 (1.168–5.050) | .016 |
| Previous cancer | 2.049 (0.951–4.225) | .067 | ||
| Retransplant | 1.989 (0.897–4.412) | .091 | ||
| cPRA (%) | 1.007 (0.988–1.016) | .136 | ||
| TAC + MMF + P | 4.871 (0.665–35.69) | .119 | ||
| DGF | 2.915 (1.460–5.848) | .002 | 2.825 (1.383–5.780) | .004 |
CI, confidence interval; TAC, tacrolimus; MMF, mycophenolate; P, prednisone.